Jacobio Pharmaceuticals Co., Ltd.
Clinical trials sponsored by Jacobio Pharmaceuticals Co., Ltd., explained in plain language.
A China-based biopharmaceutical company focused on developing cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill takes aim at Hard-to-Treat KRAS cancers Results expected Dec 2026 (estimated)
- New pill targets rare cancer mutation in early trial Results expected Jan 2027 (estimated)
- New pill aims to tame rheumatoid arthritis inflammation Results expected Jun 2027 (estimated)
-
New hope for tough pancreatic cancer? drug combo targets KRAS mutations
Disease control Recruiting nowThis study tests a new drug called JAB-23E73, which targets KRAS gene changes, combined with two standard chemotherapies (nab-paclitaxel and gemcitabine) in people whose pancreatic cancer has spread and who haven't had prior treatment. The goal is to see if the combination is saf…
Phase 1/2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests an experimental oral drug, JAB-30355, in adults with advanced solid tumors that have a specific change in the TP53 gene (called Y220C). The trial aims to find a safe dose and see if the drug can shrink tumors. About 144 participants who have already tried at leas…
Phase 1/2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New pill takes aim at Hard-to-Treat KRAS cancers
Disease control Recruiting nowThis study tests an experimental drug called JAB-23E73, taken as a pill, in people with advanced solid tumors that have a KRAS gene change. The goal is to see if it is safe, how the body processes it, and whether it can shrink tumors. About 334 participants will be enrolled acros…
Phase 1/2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New pill targets KRAS mutations in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called JAB-23E73, taken as a pill, in adults with advanced solid tumors that have a KRAS alteration. The trial has three parts: first finding a safe dose, then optimizing it, and finally checking if the drug shrinks tumors in certain cancers …
Phase 1/2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for advanced cancers? JAB-8263 enters human testing
Disease control Recruiting nowThis study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase trial.
Phase 1/2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New pill shows promise against Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental oral drug called JAB-2485 in adults with advanced solid tumors, including certain breast and lung cancers. The goal is to see if the drug is safe and can shrink tumors. About 102 participants will receive the drug, and researchers will monitor sid…
Phase 1/2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC